HEMK SWED Inactive Instrument
HEMK SWED Share Price Nasdaq Stockholm
Equities
SE0009320278
Medical Equipment, Supplies & Distribution
| Sales 2022 | 4.74M 438K 0 34.9M | Sales 2023 | 3M 277K 0 22.05M | Capitalization | 8.18M 756K 0 60.2M |
|---|---|---|---|---|---|
| Net income 2022 | -14M -1.29M - -103M | Net income 2023 | -12M -1.11M - -88.33M | EV / Sales 2022 | 0.7 x |
| Net cash position 2022 | 3.19M 295K 0 23.45M | Net cash position 2023 | 3.07M 284K 0 22.61M | EV / Sales 2023 | 1.7 x |
| P/E ratio 2022 |
-0.33
x | P/E ratio 2023 |
-1.04
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 7.12% |
More Fundamentals
* Assessed data
More news
More press releases
| Managers | Title | Age | Since |
|---|---|---|---|
Joen Averstad
CEO | Chief Executive Officer | 40 | 31/12/11 |
Robert Thorén
DFI | Director of Finance/CFO | 47 | 31/12/15 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Founder | 50 | 31/12/09 | |
| Founder | 52 | 31/12/09 | |
| Director/Board Member | 65 | 31/12/17 |
Bio Vitos Pharma AB, formerly Hemcheck Sweden AB, is a Sweden-based medical technology company. The Company produces and commercializes a service for near-patient detection of hemolysis in blood samples. The concept consists of disposable tests as well as readers that can quickly, directly upon sampling, identify hemolysed blood samples in vacuum tubes and blood gas syringes. The Company's, ruptured red blood cells, is a common reason globally why blood samples cannot be analyzed accurately and is also a biomarker for acute medical conditions. Its goal is to contribute to improved healthcare by offering user-friendly solutions for the detection of hemolysed blood samples in direct connection with blood sampling near the patient. By doing so, the Company can contribute to increased patient safety, more efficient processes and lower costs.
| 1st Jan change | Capi. | |
|---|---|---|
| -1.19% | 12.56B | |
| -6.06% | 7.68B | |
| -0.28% | 5.29B | |
| +21.77% | 5.24B | |
| +2.05% | 4.57B | |
| -51.28% | 3.29B | |
| +7.80% | 2.6B | |
| -8.63% | 2.2B | |
| -0.96% | 1.79B |
